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XPA Gene Mutations Resulting in Subtle Truncation
of Protein in Xeroderma Pigmentosum Group A
Patients with Mild Skin Symptoms
Yoshito Takahashi1, Yoko Endo1, Yoshinori Sugiyama1, Shintaro Inoue1, Masahiro Iijima2, Yasushi Tomita3,
Satoshi Kuru4, Masahiro Takigawa5 and Shinichi Moriwaki5,6
Comparisons of the clinical manifestations with gene mutations in patients with xeroderma pigmentosum
group A (XPA) have suggested that those with mutations closer to the C-terminal coding region of the XPA gene
have milder neurological and cutaneous symptoms. Here we report on four middle-aged, newly diagnosed
Japanese XPA patients whose unusually mild symptoms, especially those affecting the skin, implicate a reduced
association of a subtle defect in the C-terminus of XPA protein with skin lesions. All patients had a heterozygous
G-C transversion at the splice acceptor site of XPA intron 3. We identified previously unreported heterozygous
mutations in exon 6: a single-base insertion (690insT) in one patient and a four-base insertion (779insTT and
780insTT) in the other patients. These mutations led to the frameshift that created new premature termination
codons, resulting in the production of truncated XPA proteins. They were longer than any previously reported
truncated XPA protein, suggesting that the minimal cutaneous symptoms in these patients are due to a higher
residual level of XPA protein activity and that the subtle defect in the C-terminus of XPA protein is more closely
related to neurological impairment than to cutaneous abnormalities.
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INTRODUCTION
Xeroderma pigmentosum (XP) is an autosomal recessive
disease characterized by hypersensitivity to sunlight, abnormal
pigmentation, and a predisposition to skin cancers, especially
on sun-exposed areas (Kraemer et al., 1994; Cleaver and
Kraemer, 1995). It results from defective nucleotide excision
repair (NER), the system responsible for the repair of UV-
induced DNA damage (de Boer and Hoeijmakers, 2000).
Cultured cells derived from XP patients have a reduced DNA
repair capacity for UV-induced DNA damage and are
hypersensitive to being killed by UV (Protic-Sabljic and
Kraemer, 1985). Besides the cutaneous manifestation, neuro-
logical abnormalities such as loss of hearing, loss of tendon
reflexes, walking impairment, and intellectual impairment are
observed in about 20% of XP patients (Kraemer et al., 1987).
These symptoms are due to progressive degeneration of the
central nervous system (Robbins et al., 1991), thought to be
caused by a defective repair of lesions that are produced in
neurons by reactive oxygen species (Reardon et al., 1997; Rass
et al., 2007).
Cell fusion analysis has identified seven complementation
groups (A–G) of excision-repair-deficient cells, and there is also
a variant form that is proficient in excision repair (Kraemer,
1993; Cleaver and Kraemer, 1995). Patients with xeroderma
pigmentosum group A (XPA; OMIM #278700) generally show
the most severe symptoms (Takebe et al., 1987) and in most
cases die in their second or third decade (Sidwell et al., 2006).
The human gene complementing the defect in XPA is located
on chromosome 9q34.1 and is composed of six exons. The
protein consists of 273 amino acids (a.a.; Cleaver et al., 1999)
and is required for the early stages of NER, with a role in
damage verification and stabilizing of other NER proteins
(Berneburg and Lehmann, 2001).
In Japan, the most frequent type of XP is group A
(Moriwaki and Kraemer, 2001), and approximately 80%
of Japanese XPA patients are homozygous for the G-C
transversion mutation of the XPA gene at the splice site of
intron 3 (IV3: –1 G to C) (Satokata et al., 1990). The other
common mutations found in Japanese XPA cases are a
nonsense mutation of exon 3, which alters the 116th Tyr
codon (Y116stop), and a nonsense mutation of exon 6, which
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alters the 228th Arg codon (R228stop; Nishigori et al., 1993).
Including these three mutations, more than 20 mutation
sites in the XPA gene have been reported worldwide
(States et al., 1998; Maeda et al., 2000; Tanioka et al.,
2005; Sidwell et al., 2006). The majority are located in exons
3–5, the DNA binding region, at which the mutations tend to
occur homozygously in patients with severe manifestations.
In contrast, most milder cases have at least one allele with
a mutation in exon 6, which interacts with transcription
factor IIH (TFIIH) (Park et al., 1995; Nocentini et al., 1997). In
extensive comparisons between the distribution of mutations,
the various functional regions of the XPA protein, and the
severity of clinical symptoms, it was pointed out that the
C-terminal domain of the protein has less importance in
overall function (States et al., 1998).
In this study, we describe four XP patients with unusually
mild cutaneous abnormalities and minimal or late-onset
neurological impairment. Surprisingly, they were assigned to
complementation group A, despite their surviving to middle
age with no skin cancer. In mutational analysis, we found two
previously unreported mutations in exon 6 of the XPA gene.
RESULTS
Case reports
Case 1 (XP17HM), a 35-year-old man, was referred to the
Hamamatsu University School of Medicine, University
Hospital, Hamamatsu, Japan. Case 2 (XP21HM), a 30-year-
old woman, was referred to the Nagoya University Hospital,
Nagoya, Japan. Case 3 (XP42HM), a 40-year-old woman, and
case 4 (XP43HM), a 45-year-old man, were referred to the
Suzuka National Hospital, Suzuka, Japan. XP42HM and
XP43HM are siblings. Each of these patients presented for
consultation because he or she had a mild neurological
manifestation and a history of moderate sun sensitivity.
Their clinical characteristics are summarized in Table 1. Mild
dermatological abnormalities, such as mild freckling and
telangiectasia on the face, were present in all of the patients
(Figure 1). No skin cancer has developed. All of them have
microcephaly, intellectual impairment, ataxia dysarthria,
involuntary movement, and hyporeflexia (or areflexia). These
neurological abnormalities are minimal or were of late onset
but are progressing slowly and gradually.
Classification into a mild form of XP on the basis of UV survival
and UV-induced unscheduled DNA synthesis assays
UV survival and UV-induced unscheduled DNA synthesis
(UDS) of primary fibroblasts from the patients were
Table 1. Clinical and cellular characteristics of patients in this study as well as a typical severe XPA case and
normal subjects
Case Age/Sex
Abnormality in
pigmentation
Skin
cancer
Neurological
abnormality1
Fibroblast
strain UDS (%)2
UV survival
(D37; Jm
2)3
1 35/M Mild – + XP17HM 17 0.9
2 30/F Mild – + XP21HM 21 1.4
34 40/F Mild – ++ XP42HM 21 0.8
44 45/M Mild – ++ XP43HM 32 0.9
XPA5 12/F Severe –6 +++ XP12HM 3 0.4
Normal 42/M None – – N-42 100 5.9
Abbreviations: F, female; M, male; UDS, unscheduled DNA synthesis; XPA, xeroderma pigmentosum group A.
1All the patients have microcephaly, intellectual impairment, ataxia dysarthria, involuntary movement, and hyporeflexia/areflexia. + Mental retardation with
minimal, if any, abnormal neurological reflexes; ++ mental retardation and abnormal neurological reflexes; +++ inability to walk because of severe
neurological abnormality.
2A global ability of nucleotide excision repair system.
3UV survival was determined on the basis of colony-forming ability.
4Cases 3 and 4 are siblings.
5Typical severe XPA patients.
6This patient began to protect herself from UV by using sunscreen after she was diagnosed with XPA at the age of 3 years.
Figure 1. Unusually mild cutaneous features of four patients with xeroderma
pigmentosum. (a) XP17HM; (b) XP21HM; (c) XP42HM; (d) XP43HM. Each
patient’s cutaneous symptoms consist only of mild freckling and few, if any,
telangiectasias on the face.
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compared, according to colony-forming ability (Table 1), with
those from a normal subject and a typical XPA patient
(XP12HM). The D37 (dose that results in 37% cell survival) of
cells from the four patients was 0.8–1.4 Jm2, which was much
lower than that of cells from a normal subject (5.9 Jm2);
however, these cells were less sensitive than those in a typical
XPA patient (0.3–0.4 Jm2). The levels of UV-induced UDS in
these cells were 14–24% of those of cells from normal subjects,
similar to the levels for an intermediate group of XP patients.
Assignment to XP complementation group A
Complementation analysis was carried out with a host-cell
reactivation assay in which cells were cotransfected with a
UV-damaged luciferase gene expression vector, with expres-
sion vectors harboring cloned wild-type XP complementary
DNA (cDNA). Increased luciferase activity was observed
when the XPA gene was transfected into cells from these
patients, but luciferase activity was very low in cotransfection
with the other XP genes (Figure 2a). Thus, only the XPA gene
complemented the DNA repair defect. This result indicates
assignment of these cells to XP complementation group A.
Heterozygous mutations in the XPA gene common to Japanese
patients
To characterize the mutation of the XPA gene in these
patients, we first confirmed the presence of the most common
Japanese mutation (IV3: –1 G to C) by AlwNI PCR-restriction
fragment-length polymorphism (RFLP) analysis in amplified
DNA fragments of exon 3, including the flanking intron. DNA
from these patients showed three bands, whereas two bands
appeared in the severe XPA patient, who has this mutation
homozygously (Figure 2b). This observation indicates that the
patients with mild symptoms had the heterozygous mutation
common to Japanese patients. We also examined the
other common Japanese mutations (Y116stop and R228stop)
using RFLP analysis (Nishigori et al., 1994). However, these
mutations were not found (data not shown).
Two insertion mutations in exon 6 of the XPA gene
heterozygously
To identify the mutation sites that could not be detected by
RFLP analysis, we performed a sequence analysis on each
exon of the genomic DNA from these patients. In XP17HM,
the heterozygous sequence signal that started from nucleotide
690 in exon 6 was detected (Figure 3a), showing that there
was an insertion of a nucleotide (690insT). In the other
three patients, the heterozygous sequence signal that started
from nucleotide 779 in exon 6 was detected (Figure 3b),
showing that there was an insertion of four nucleotides
(779insTT 780insTT). These previously unreported mutations
are located closer to the C-terminus than any previously
reported mutations that cause truncation of the XPA protein
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Figure 2. Each patient was diagnosed with xeroderma pigmentosum group A (XPA) and had a common Japanese mutation heterozygously. (a) Host-cell
reactivation assay was performed via cotransfection of the UV-C-treated reporter plasmid (pGL2Luc) with xeroderma pigmentosum complementary DNA (XPA
(closed circle), XPB (open circle), XPC (closed diamond), XPD (open diamond), XPF (closed square), or XPG (open square)) or control plasmid pcDNA3 (open
triangle) into fibroblasts from patients. DNA repair capacity was defined as the percentage of residual luciferase activity after repair of UV-irradiated DNA
compared with that of nonirradiated DNA. Values taken from two independent experiments are depicted. (b) DNA extracted from fibroblasts was analyzed
by restriction fragment-length polymorphism as described in Materials and Methods. The polymorphism of patients with a mild phenotype (genotype
G/C) showed three bands, whereas normal subjects (genotype G/G) displayed one band and severe XPA patients (genotype C/C) had two.
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(Figure 3c). Mutation 690insT caused a frameshift at amino
acid position 231, resulting in a stop codon 15 amino acids
downstream (Figure 3d). Another mutation, 779insTT
780insTT, caused a frameshift at amino acid position 260,
resulting in a stop codon eight amino acids downstream
(Figure 3e). The predicted sizes of XPA proteins are 244a.a. in
XP17HM and 267a.a. in the other three patients.
Expression of the truncated XPA protein
We next determined whether the predicted frameshift XPA
protein is indeed expressed in cells from these patients.
Western analysis revealed two bands as XPA proteins in the
cell extract from normal subjects (Figure 4a), consistent with
a previous report (Miura et al., 1991). No XPA protein was
detected in the severe XPA patient. In each mild XPA patient,
a significant band level was detected at a position lower than
that for normal protein. The band sizes were estimated at
91% of that of normal protein in XP17HM and 97% of that in
the other three patients. These estimated sizes were almost
consistent with the predicted size, which was 89% (244/
273a.a.) for XP17HM and 98% (267/273a.a.) in the other
three patients. To confirm these estimates, we analyzed
another patient (XP41HM) who has a nonsense mutation
(R228stop) with truncated XPA protein, the predicted size of
which is 83% (227/273a.a.) of the normal protein. The
estimated size according to western analysis was 82%,
showing that the mutations identified in this study cause the
truncation of XPA protein. These findings suggest that the
unusually mild symptoms might be due to the higher residual
level of functional activity of truncated XPA proteins.
Reduced levels of XPA mRNA
To investigate whether the expression levels of XPA proteins
correlate with the amounts of XPA mRNA in these patients,
we performed northern analysis. Two bands of about
1.3–1.4 kb and 1.0–1.1 kb were detected in the extract from
cells of a normal subject (Figure 4b), consistent with a
previous study (Tanaka et al., 1990). In the mild XPA patients,
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Figure 3. Two insertion mutations were identified in exon 6 of the xeroderma pigmentosum group A (XPA) gene heterozygously. (a) The genomic sequencing
of exon 6, showing a single-base insertion at nucleotide 690. (b) The genomic sequencing of exon 6, showing a four-base insertion at nucleotides 779 and
780. (c) Map of XPA gene and mutations. The mutations close to the C-terminus reported in the mild cases are indicated. The three Japanese common mutations
are underlined. Mutations identified in this study are indicated by italics. Exon 6 is responsible for interacting with transcription factor IIH. (d) The base
sequences of genomic DNA with coding amino acids corresponding to a normal subject and to a patient with the 690insT mutation. (e) The base sequences
of genomic DNA with coding amino acids corresponding to a normal subject and to patients with the 779insTT, 780insTT mutation.
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reduced levels of XPA mRNA were detected; these were
comparable to those of the smaller mRNA in cells from
XP24HM, who has the common Japanese mutation homo-
zygously, suggesting a destabilization of XPA mRNA because
of premature termination codons. Therefore, the expression
levels of the truncated XPA protein were not relevant to the
amounts of XPA mRNA.
DISCUSSION
We have characterized two previously unreported mutations
in the XPA gene via genetic analysis of four middle-aged XPA
patients (XP17HM, XP21HM, XP42HM, and XP43HM). An
unexpected finding was that these patients were assigned to
XP complementation group A, because, despite being of
middle age, they manifested an unusually mild phenotype for
XPA, the severest form of XP. Ordinarily, XPA patients are
diagnosed on the basis of their severe photosensitivity and
developmental delay starting in the first decade of life. The
patients in this study have late-onset progressive neurological
abnormalities but no cutaneous features other than mild
freckles and telangiectasia. Hence, the definitive diagnosis of
XP had not been made earlier in their lives.
Thus far, more than 20 mutations of the XPA gene have
been identified. It is thought that the severity of symptoms of
XPA patients depends on the residual activity of the abnormal
XPA protein. The typical XPA patients showing both severe
neurological abnormalities and extreme photosensitivity have
mutations within exons 3–5, almost all of which are deletions
or missplicings seriously disrupting the structure. Because
these exons encode the DNA binding domain, the severe
manifestations are thought to result from the loss of pivotal
NER function. Some patients with missplicing in the DNA
binding domain show less severe symptoms. It is more likely
that these mutations allow the production of a small amount
of normal protein by alternative splicing (States et al., 1998).
On the other hand, four mutations close to the C-terminus
of the XPA protein have been reported to be associated with
milder symptoms (Figure 3c). Two are located in exon 5, but
outside the DNA binding region, and the others are in exon 6
(Satokata et al., 1992b; Nishigori et al., 1993; Cleaver et al.,
1995; Maeda et al., 1995; Sato et al., 1996). The mutations in
exon 5 are an insertion mutation (661insA) and the G-C
transversion (G673C) that may allow the production of
truncated XPA protein; the protein expression was actually
confirmed in a later mutation. The mutations in exon 6 are a
nonsense mutation (R228stop) and a missense mutation
(H244R). The former is one of the common Japanese
mutations. Almost all patients with the above-mentioned
mutations close to the C-terminus of the XPA protein were
reported to show mild cutaneous symptoms and minimal or
late-onset neurological signs. Given that exon 6 interacts with
TFIIH, these mutations may cause a decrease in the ability to
bind to TFIIH. Therefore, this C-terminal domain is thought to
have lesser importance for overall function.
The mutations identified in this study are located closer to
the C-terminus than are any previously reported mutations
that cause truncation of the XPA protein. They were all
compound heterozygote with the most common Japanese
mutation (IV3: –1 G to C), which results in severe disruption
of the XPA protein, indicating that the newly identified
mutations are causative of very mild symptoms. Specifically,
the cutaneous symptoms were limited to freckles and
telangiectasia and the neurological signs were of late onset
and slow to progress. These observations and previous
findings suggest that the minimal cutaneous symptoms in
these patients are due to the higher residual level of
functional activity of XPA protein that has partially lost its
ability to interact with TFIIH. In fact, the truncated XPA
protein was significantly expressed in each patient, and the
truncation of these proteins was much less than that of any
XPA protein previously reported (Mimaki et al., 1996; Sato
et al., 1996). Thus, the subtle defect in the C-terminus of XPA
protein seems to be more closely related to neurological
impairment than to cutaneous abnormalities. This possibility
merits investigation, e.g., by comparing the ability of
truncated XPA proteins to bind to TFIIH in mild cases.
Northern analysis revealed that the amount of XPA
mRNA was markedly reduced in all cases in this study,
suggesting that XPA mRNA was unstable because of
premature termination. However, in XP17HM (690insT),
considerable expression of truncated XPA protein was
observed, whereas its expression levels were reduced in the
37
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Figure 4. A significant expression of truncated XPA protein and a reduced
expression of XPA mRNA in each patient. (a) A volume of 50 mg of total
protein from N-3 (normal, lane 1), N-75 (normal, lane 2), XP21HM (lane 3),
XP42HM (lane 4), XP43HM (lane 5), XP17HM (lane 6), XP 41 HM (mild XPA,
lane 7), and XP24HM (severe XPA, lane 8) was analyzed for expression of the
XPA protein by western blotting. Equal loading/transfer was confirmed by
amido-black staining of membranes. (b) A volume of 1 mg of poly (A)þ RNA
from N-3 (normal, lane 1), XP17HM (lane 2), XP21HM (lane 3), XP42HM
(lane 4), XP43HM (lane 5), XP24HM (severe XPA, lane 6) was subjected to
electrophoresis and analyzed by northern blotting with DIG-labeled XPA and
GAPDH probe. The GAPDH mRNA is shown as the internal standard. The
size of marker RNA is indicated (lane M).
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other patients (779insTT, 780insTT). The truncated protein
derived from the mutation of 690insT may be difficult to
degrade. The reason that XP17HM is not less sensitive than
the other patients might be that a shorter length of the
truncated protein offsets the greater amount. Whatever the
reason, no correlation between the expression levels of the
truncated XPA protein and amounts of XPA mRNA was
found, implying that each type of truncated XPA has a
different level of stability. Therefore, the ability to bind with
TFIIH might also be different for each type of mutant XPA
protein.
Neurological abnormalities observed in XP patients are
postulated to result from the insufficient repair of oxidative
DNA lesions in the central nervous system, in which
the production rate of reactive oxygen species is higher
(Rass et al., 2007). However, a direct correlation between
unrepaired oxidative DNA damage and NER deficiency has
not been identified. NER consists of two pathways: global
genome repair and transcription-coupled repair (TCR). The
former repairs nontranscribed DNA lesions throughout the
genome; the latter repairs lesions in actively transcribed DNA
more rapidly (Moriwaki and Takahashi, 2008). Nondividing
neurons in the central nervous system are among the most
transcriptionally active cells in the body, suggesting that TCR
predominates. Cockayne syndrome, in which TCR is defi-
cient, is known to have neurological defects as a clinical
feature but is not characterized by a predisposition to skin
cancers (Moriwaki and Kraemer, 2001). These observations
imply that TCR is more defective than global genome repair
in the studied cases. Therefore, any correlations between the
extent of truncation of the C-terminal region and the binding
activity of XPA protein to TFIIH may give us insight into the
pathogenic mechanisms of neurological defects in XP
patients from the view of differences between global genome
repair and TCR.
Recently, previously unreported mutations in the XPA
gene that are associated with the mild phenotype have been
identified one after another, including the mutations in this
study, thanks to the development of advanced molecular
diagnosis techniques. Patients with the mild phenotype show
neither skin cancer (this study) nor neurological manifesta-
tions (Tanioka et al., 2005; Sidwell et al., 2006) and are
unlikely to be diagnosed with XPA in the absence of genetic
analysis. The patients in this study are compound hetero-
zygotes for a common Japanese mutation (IV3: –1 G to C) and
for previously unreported insertion mutations (690insT or
779insTT, 780insTT). It is known that the homozygote for the
nonsense mutation in exon 6 (R228stop) shows a milder
phenotype than the heterozygote for this mutation (Satokata
et al., 1992a). Therefore, if the homozygote for the mutations
we identified exists, it may account for the extremely mild
symptoms. It is interesting to analyze the allele frequency of
these mutations from the point of view that these mutations
may increase the risk for skin and neural aging in subjects
who are not clinically recognized as XP patients. If these
mutations are found at a comparatively high frequency, they
may be used to assess the risk factor of photoaging in a
manner similar to the use of single-nucleotide polymorph-
isms. By contrast, laboratory investigations based on NER
abnormality have failed to show clinical and biological
differences between XP carriers (heterozygote) and normal
subjects (Moriwaki et al., 1993). However, a recent study, in
which large-scale screening of Japanese carriers of the
founder mutation (IV3: –1 G to C) was performed, revealed
that the ratio of Japanese XPA heterozygotes carrying the
founder mutation is nearly 1% (Hirai et al., 2006), which is
threefold higher than previously estimated (Maeda et al.,
1997). In this regard, further analysis of XPA patients with the
mild phenotype may provide clues to the relationship
between XP mutations and the risk for aging of cutaneous
and nervous tissues.
MATERIALS AND METHODS
Cells and media
Cultured fibroblasts designated as XP17HM, XP21HM, XP42HM,
and XP43HM derived from cases 1, 2, 3, and 4, respectively, were
all established from skin biopsy specimens from the patients.
We also used cultured fibroblasts as controls, N-42 and N-75
derived from normal subjects, XP12HM and XP24HM derived
from typical XPA patients with the homozygous Japanese com-
mon mutation (IV3: –1 G to C), and XP41HM derived from a
mild XPA case with a nonsense mutation (R228stop). Analyses
were performed with a previously established fibroblast strain
(N-3; Moriwaki et al., 1992) and with the nine cell strains men-
tioned above, after obtaining written informed consent from the
donors. The study was approved by the Institutional Review
Board of Osaka Medical College and conducted according to the
Declaration of Helsinki Principles. The cells were maintained in
DMEM (Sigma, St Louis, MO) supplemented with 15% fetal bovine
serum (JRH Biosciences, Lenexa, KS) at 37 1C in a 5% CO2
atmosphere.
Assessment of UV survival
Cells were seeded on 60-mm dishes at 5 102–2 104 cells per
well. After incubation for 18 hours, cells were irradiated by UV and
incubated for 1–2 weeks until colonies were formed (with more than
50 cells in a colony). Irradiation was performed with germicidal
lamps (GL-10, Toshiba, Tokyo, Japan; predominantly 254 nm) at a
dose of up to 20 Jm2, as measured using a UV radiometer (UVR-1,
Topcon, Tokyo, Japan). After fixation with formalin and staining with
crystal violet, the colonies were counted.
Measurement of UV-induced UDS
Cells were seeded on a glass coverslip in 35-mm dishes. After
incubation for 18 hours, cells were UV irradiated with germicidal
lamps at a dose of 30 Jm2, followed by incubation with 10 mCiml1
of methyl-[3H]-thymidine (GE Healthcare, Buckinghamshire, UK) for
3 hours. After labeling, cells were fixed with Carnoy’s solution and
washed with 5% trichloroacetic acid. The glass coverslips were
dipped in nuclear track emulsion, NTB3 (Eastman Kodak, Rochester,
NY, USA), for autoradiography. The number of grains per interphase
nucleus was scored for 100 nuclei in each specimen. UDS was
determined by the percentage of net count when the net count of
cells from a normal subject is 100%. Net count is determined by
subtracting the mean grain count of nonirradiated cells from that of
UV-irradiated cells.
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Host-cell reactivation and assignment of XP complementation
group
The reporter plasmid, pGL2Luc (Promega, Madison, WI), which
harbors the luciferase gene, was used to measure post-UV DNA
repair capacity by host-cell reactivation. The reactivation was
performed as described previously (Takahashi et al., 2005), with
slight modification. Briefly, fibroblasts were seeded on 24-well
plates at 2 104 cells per well. After incubation for 18 hours, the
cells were transfected with the UV-irradiated or nonirradiated
plasmid (0.2 mg DNA per well) with the Effectene transfection
reagent (Qiagen, Hilden, Germany). After incubation for 48 hours,
the luciferase activity in the cell lysate was measured using the
PicaGene luciferase assay system (Toyo Ink, Tokyo, Japan). DNA
repair capacity was expressed as the percentage of residual
luciferase activity after repair of UV-irradiated DNA compared with
nonirradiated DNA. In order to assign the patients’ fibroblasts to a
specific XP complementation group, simultaneous cotransfection
was performed with pcDNA3 expression vectors containing different
XP cDNAs (XPA, XPB, XPC, XPD, XPF, or XPG) along with the
reporter plasmid (Fujimoto et al., 2005).
PCR-RFLP analysis
For detection of the common Japanese mutation (IV3: –1 G to C),
PCR-RFLP analysis was performed as described previously (Nishigori
et al., 1994). Briefly, DNA was extracted from cells using a QIAamp
DNA isolation kit (Qiagen) and amplified by PCR with EX Taq DNA
Polymerase (Takara Bio, Shiga, Japan) and primers as follows: sense
primer 50-GGGAATTCTTGCTGGGCTATTTGCAAAC-30 and anti-
sense primer 50-GGGGATCCGCCAAACCAATTATGACTAG-30. The
PCR steps consisted of 30 cycles of denaturation at 94 1C for
30 seconds, annealing at 59 1C for 30 seconds, and elongation at
72 1C for 1minute. Thereafter, the 328 bp PCR product was digested
by restriction endonuclease AlwNI (New England Biolabs, Beverly,
MA) for 3 hours at 37 1C. The G-C substitution creates a new
cleavage site for AlwNI. The AlwNI cuts the 328 bp fragment,
resulting in two fragments (84 and 244bp). The digested PCR
products were analyzed by Agilent 2100 Bioanalyzer using a DNA
1000 kit (Agilent Technologies, Santa Clara, CA).
Nucleotide sequence analysis
All six exons and flanking introns of the XPA gene in DNA extracted
from cells were amplified by PCR with EX Taq DNA Polymerase
(Takara Bio), and the PCR products were sequenced using an ABI
PRISM 377 DNA Sequencer (Applied Biosystems, Foster City, CA).
The PCR steps consisted of 30 cycles of denaturation at 95 1C for
20 seconds, annealing at 50 1C for 20 seconds, and elongation at
72 1C for 1minute. Sequencing primers are listed in Supplementary
Table S1 online.
Western analysis
The nuclear fraction was extracted from cells using a ReadyPrep
Protein Extraction Kit (Bio-Rad Laboratories, Richmond, CA), and
the protein concentrations were assayed using a DC Protein Assay
kit (Bio-Rad Laboratories). Electrophoresis, transfer, and chemi-
luminescent detection were performed as described previously
(Takahashi et al., 2005). A volume of 50mg per lane of each extract
was run. The transfer membrane (Polyscreen, NEN Life Science
Products, Boston, MA) was incubated with 1:1,000 diluted anti-XPA
(Clone 12F5, Neomarkers, Fremont, CA) as a primary antibody,
followed by incubation with a 1:5,000 dilution of horseradish
peroxidase–conjugated goat anti-mouse IgG (Hþ L; ICN Biomedi-
cals, Aurora, OH).
Northern analysis
RNA was extracted from cells using a Micro-FastTrack 2.0 mRNA
Isolation Kit (Invitrogen, Carlsbad, CA). RNA samples were separated
by electrophoresis on a 0.8% formaldehyde/agarose gel and
transferred to a nylon membrane (Roche, Basel, Switzerland).
Preparation of DIG-labeled RNA probe, hybridization, and chemi-
luminescent detection were performed as described previously (Sayo
et al., 2002), with slight modification. The cDNA of human XPA
genes was generated using reverse transcriptase–PCR with the
following primers: sense primer 50-CATCATTCACAATGGGGTGA-
30 and anti-sense primer 50-GTCAGTTCATGGCCACACAT-30. The
expected cDNA fragments were ligated into the TA-cloning site of
pGEMTeasy (Promega). In vitro transcription was performed with
cloned cDNA to synthesize antisense RNA probes using a DIG RNA
labeling kit (Roche). Membranes were rehybridized with a DIG-
labeled glyceraldehyde-3-phosphate dehydrogenase antisense RNA
probe prepared from commercially available human glyceraldehyde-
3-phosphate dehydrogenase cDNA (Clontech, Palo Alto, CA).
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